Artikel
The therapeutic dilemma: (re)administration of anticoagulation therapy after intracranial hemorrhage
Antikoagulation nach intrakranieller Blutung – ein therapeutisches Dilemma
Suche in Medline nach
Autoren
Veröffentlicht: | 23. April 2004 |
---|
Gliederung
Text
Objective
Frequent indications for anticoagulation are mechanical heart valves, atrial fibrillation, and deep vein thrombosis. Anticoagulant-related intracranial hemorrhage (ICH) represents a difficult clinical choice. Early readministration of anticoagulation therapy (ACT) may increase the hemorrhage, while reversal of ACT exposes patients at risk for systemic thrombembolic events involving the pulmonary and cerebral vascular territories. The aim of this literature study was to assess the quality of scientific evidence concerning type and timing of ACT after ICH in patients at high thromboembolic risk in relation to embolic complications and recurrent bleeding.
Methods
The MEDLINE database (1966-11/2003) was searched for relevant articles dealing with this subject. The literature was estimated in their design, results, and quality of statistical analysis.
Results
There are no randomised controlled trials or prospective observational studies about the risks associated with reversal and recommencing anticoagulation in patients with ICH. Retrospective data suggest that a temporary interruption of ACT with phenprocoumone for about two weeks is safe for patients with mechanical heart valves and the risk of recurrent bleeding after restarting oral ACT is low. The administration of unfractionated intravenous heparin during cessation of phenprocoumon cannot be generally advocated on the basis of an estimated risk-benefit ratio. An unresolved issue is the safety and effectiveness of low-dose subcutaneous heparin in patients with residual chronic subdural hematoma needing ACT.
Conclusions
Due to the low statistical power of the available data there is a considerable lack of evidence concerning the potential hazards of management of ACT in patients with ICH.